- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01420978
Cerebrospinal Fluid (CSF) Drainage Study
High Volume Cerebrospinal Fluid Diversion in the Management of Aneurysmal Subarachnoid Hemorrhage: A Pilot Study
When patients suffer a subarachnoid hemorrhage (bleeding around the brain), they often develop hydrocephalus. This is an enlargement of the fluid-filled spaces (ventricles) in the brain. Standard-of-care treatment includes placing an external ventricular drain (EVD) to drain off fluid. Eventually the EVD is weaned with the goal of removing it. Occasionally a patient does not tolerate this and a permanent surgery needs to be done to internalize a shunt.
Though this is done commonly and routinely throughout the world, there are no good studies to address how to optimally set the EVD level and how fast to wean it. Most set the EVD to a level of around 15 mmHg. The investigators hypothesize that setting the EVD lower (which will allow higher volume Cerebrospinal Fluid (CSF) drainage through the EVD) will improve perfusion at the level of the microcirculation in the brain, and result in improved neurologic outcomes.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32224
- Mayo Clinic in Florida
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Mayo Clinic in Rochester
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
- Age ≥ 18 years
- Diagnosis of acute subarachnoid hemorrhage (SAH), confirmed with noncontrast head CT
- SAH is suspected to be aneurysmal in source
- Clinical management requires placement of EVD within 2 days of suspected time of hemorrhage
Exclusion Criteria
- Age < 18 years
- SAH of traumatic or non-aneurysmal etiology
- Patients treated with lumbar drains
- EVD placement ≥ 3 days after suspected time of hemorrhage
- Known contraindication to induction of relative intracranial hypotension (e.g. acute subdural hematoma)
- Pre-morbid mRS ≥ 3
- EVD that is suboptimally placed by CT obtained after EVD placement (i.e. EVD not in the ventricular system)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: High volume CSF diversion
The EVD will be set to an initial level of 5 mmHg.
The drain will remain in place at a level of ≤ 5 mmHg until at least day 10 after SAH before a weaning trial is attempted.
|
CSF drainage
|
Comparateur actif: Conventional CSF diversion
The EVD will be set to a level of 15 mmHg for as long as needed for the treatment of hydrocephalus, and subsequently weaned at the discretion of the treating physician.
Lowering the level of the EVD can be considered by the treating physician if sustained intracranial hypertension occurs
|
CSF drainage
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Modified Rankin Scale
Délai: 90-days
|
The primary outcome is clinical outcome at 90 days.
A favorable outcome is defined as a score of 1 or 2 on the modified Rankin Score (mRS) and poor outcome defined as a mRS of 3-6.
This assessment will be made by a clinician who was blinded to the patient's CSF diversion treatment arm.
|
90-days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Infarction
Délai: 90-days
|
Presence of radiologic infarction
|
90-days
|
Vasospasm
Délai: 90-days
|
Evidence of vasospams based upon TCD and/or angiography
|
90-days
|
Shunt placement
Délai: 90-days
|
Rate of shunt placement
|
90-days
|
Ventriculitis
Délai: 90-days
|
Rate of ventriculitis
|
90-days
|
Modified Rankin Scale
Délai: Hospital discharge (average 3 weeks)
|
Modified rankin Scale upon discharge from the hospital
|
Hospital discharge (average 3 weeks)
|
MMSE
Délai: 90-days
|
Cognitive status evaluated using the MMSE
|
90-days
|
Length of ICU stay
Délai: Average 3 weeks
|
Evalute the average length of ICU stay for this patient population.
|
Average 3 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Giuseppe Lanzino, MD, Mayo Clinic
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 11-002713
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur CSF Diversion
-
Case Western Reserve UniversityActif, ne recrute pasSyndrome de stress de l'aidant | Stresser | Démence | La maladie d'Alzheimer | DeuilÉtats-Unis
-
Orasis Pharmaceuticals Ltd.Complété
-
The First Hospital of Jilin UniversityRecrutementLymphome | Neutropénie induite par la chimiothérapieChine
-
Peking UniversityInconnue
-
Air Force Military Medical University, ChinaInconnue
-
Chongqing University Cancer HospitalCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Recrutement
-
Zhongnan HospitalPas encore de recrutementFacteur de stimulation des colonies de granulocytesChine
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.Pas encore de recrutement
-
Xiamen Amoytop Biotech Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesComplété
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Beijing Friendship HospitalInconnueSyndrome hémophagocytaireChine